/BIOA
BIOA Stock - BioAge Labs, Inc.
Healthcare|BiotechnologyNASDAQ
$13.39+8.16%
+$1.01 (+8.16%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).29
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-10.4%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BIOA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.26 – $13.52
TARGET (TP)$12.00
STOP LOSS$12.32
RISK/REWARD1:-1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.76
52W High$13.41
52W Low$2.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-78,194,000 | $-48,400,000 | $-39,969,000 |
| Net Income | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-6.63 | $-8.55 | $-5.32 |
Company Overview
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
50%
Hold / Neutral
3
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish3 Neutral/Bearish
Price Targets
$21
Average Target
↑ 56.8% Upside
Now
$5
Low
$21
Average
$45
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2025 | Morgan Stanley | Upgrade | Equal Weight | $12 |
| October 22nd 2025 | Citigroup | Upgrade | Buy | $10 |
| February 28th 2025 | William Blair | Initiation | Market Perform | - |
| December 10th 2024 | Morgan Stanley | Downgrade | Underweight | $5← $40 |
| December 9th 2024 | Jefferies | Downgrade | Hold | $7← $42 |
| December 9th 2024 | Citigroup | Downgrade | Neutral | $7← $45 |
| October 21st 2024 | Citigroup | Initiation | Buy | $45 |
| October 21st 2024 | Jefferies | Initiation | Buy | $42 |
| October 21st 2024 | Morgan Stanley | Initiation | Overweight | $40 |
Earnings History & Surprises
BIOABeat Rate
40%
Last 5 quarters
Avg Surprise
-206.0%
EPS vs Estimate
Beats / Misses
2/3
Last 12 quarters
Latest EPS
$-0.56
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
No data
Q4 24
-830.6%
$-6.70vs$-0.72
Q1 25
-239.7%
$-1.97vs$-0.58
Q2 25
+30.8%
$-0.36vs$-0.52
Q3 25
-7.1%
$-0.60vs$-0.56
Q4 25
+16.4%
$-0.56vs$-0.67
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-1.01 | — | — | — |
Q1 2026 | Mar 19, 2026 | $-1.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.67 | $-0.56 | +16.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.56 | $-0.60 | -7.1% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.52 | $-0.36 | +30.8% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.58 | $-1.97 | -239.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.72 | $-6.70 | -830.6% | ✗ MISS |
Q3 2024 | Sep 26, 2024 | — | $-1.80 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-1.74 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-2.81 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-1.96 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-2.30 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-1.48 | — | — |
Q1 2018 | Mar 27, 2018 | $-0.72 | — | — | — |
Latest News
Morgan Stanley Upgrades Bioage Labs to Equal-Weight, Raises Price Target to $12
📈 PositiveBenzinga•Dec 8, 2025, 05:07 PM
BioAge Labs shares are trading higher after the company announced interim data from the ongoing Phase 1 SAD / MAD clinical trial evaluating BGE-102.
📈 PositiveBenzinga•Dec 4, 2025, 05:56 PM
BioAge Labs Data From BGE-102 Study Shows Well-Tolerance, Strong Target Engagement In Patients With Cardiovascular Risk Factors
📈 PositiveBenzinga•Dec 4, 2025, 02:06 PM
Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M
📈 PositiveBenzinga•Nov 6, 2025, 10:05 PM
Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $15
📈 PositiveBenzinga•Oct 29, 2025, 07:55 PM•Also:
BioAge Labs shares are trading higher. Citigroup recently upgraded the stock from Neutral to Buy and raised its price target from $5 to $10.
📈 PositiveBenzinga•Oct 23, 2025, 04:41 PM•Also:
BioAge Labs shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $5 to $10.
📈 PositiveBenzinga•Oct 22, 2025, 02:01 PM•Also:
Citigroup Upgrades Bioage Labs to Buy, Raises Price Target to $10
📈 PositiveBenzinga•Oct 22, 2025, 11:21 AM•Also:
Frequently Asked Questions about BIOA
What is BIOA's current stock price?
BioAge Labs, Inc. (BIOA) is currently trading at $13.39 per share. The stock has moved +8.16% today.
What is the analyst price target for BIOA?
The average analyst price target for BIOA is $12.00, based on 1 analyst.
What sector is BioAge Labs, Inc. in?
BioAge Labs, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BIOA's market cap?
BioAge Labs, Inc. has a market capitalization of $0.48 billion, making it a small-cap company.
Does BIOA pay dividends?
No, BioAge Labs, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACB
Aurora Cannabis Inc.
$4.96
Mkt Cap: $0.3B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
CGC
Canopy Growth Corporation
$1.48
Mkt Cap: $0.4B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
LFCR
Lifecore Biomedical, Inc.
$8.04
Mkt Cap: $0.3B
OMI
Owens & Minor, Inc.
$2.84
Mkt Cap: $0.2B
TKNO
Alpha Teknova, Inc.
$4.65
Mkt Cap: $0.2B
Explore stocks similar to BIOA for comparison